Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMPle: Empagliflozin Effects on Myocardial Perfusion in Type 2 Diabetes
2016-003743-10Phase 4Completed
- Sponsor
- Herlev og Gentofte Hospital
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of empagliflozin in type 2 diabetes mellitus (T2DM) and cardiac morbidity (2 arms), sponsored by Herlev og Gentofte Hospital. Primary endpoint: Change in myocardial flow reserve. Started Oct 2016; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on 2016-003743-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003743-10.